At Intellipharmaceutics, we are engaged in the research, development and commercialization of pharmaceutical products, both novel and generic, with a particular emphasis in the controlled-release & opioid abuse deterrence space. Intellipharmaceutics also operates a contract analytical services lab in Toronto that provides Methods Development, Validation & Transfer, Quality Control Testing, Stability Testing and Category 1 Abuse Deterrent Studies. Intellipharmaceutics International is currently trading on the OTCQB and TSX (OTCQB: IPCIF; TSX: IPCI).
View Top Employees from Intellipharmaceutics InternationalWebsite | http://www.intellipharmaceutics.com |
Ticker | IPCI |
Revenue | $1 million |
Funding | $10 million |
Employees | 35 (28 on RocketReach) |
Founded | 1998 |
Address | 30 Worcester Rd, Toronto, Ontario M9W 5X2, CA |
Phone | (416) 798-3001 |
Fax | (416) 798-3007 |
Technologies |
JavaScript,
HTML,
PHP
+14 more
(view full list)
|
Industry | Pharmaceutical Manufacturing, Pharmaceuticals, Biotechnology, Generic Pharmaceuticals, Healthcare, Science and Engineering, Controlled-Release Drug Delivery, Health Care, Hypermatrix (TM) Technology, Pharmaceutical |
Web Rank | 4 Million |
Keywords | Intellipharmaceutics International |
Competitors | Alexza / Ferrer, DelSiTech Ltd, Elorac, Inc, Lipocine Inc., QUEST PHARMA LIMITED |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies |
Looking for a particular Intellipharmaceutics International employee's phone or email?
The Intellipharmaceutics International annual revenue was $1 million in 2024.
Auwal Odidi is the Director of Corporate Affairs and Operations of Intellipharmaceutics International.
28 people are employed at Intellipharmaceutics International.
Intellipharmaceutics International is based in Toronto, Ontario.
The NAICS codes for Intellipharmaceutics International are [3254, 32541, 325, 32].
The SIC codes for Intellipharmaceutics International are [283, 28].